For these breast cancer subtypes, the presence of immune infiltrates is associated with a good prognosis in patients treated with standard neoadjuvant chemotherapy or trastuzumab (for HER2-overexpressing tumors) (Denkert et al., 2018; Ochi et al., 2019). Here, ERBB2 is linked to breast carcinoma.